Skip to content

Gross margin at other companies

Amgen logo
AmgenAMGN
68.3%+5.3pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
99.3%-0.5pp
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
36.7%+4.1pp
Incyte logo
IncyteINCY
92.5%-0.2pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
67.8%-0.5pp
Nuvation Bio logo
Nuvation BioNUVB
54.3%+39.5pp

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.25B+1,531%
Enterprise value$2.33B+874%
P/S40.5×+38.9×

Profitability

See full
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Calculated from Nektar Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's gross margin?
Nektar Therapeutics (NKTR) reported gross margin of 100% in Q4 2025.
How has Nektar Therapeutics's gross margin changed year-over-year?
Nektar Therapeutics's gross margin increased by 45.3% year-over-year, from 68.8% to 100%.
What is the long-term trend for Nektar Therapeutics's gross margin?
Over 5 years (2020 to 2025), Nektar Therapeutics's gross margin has grown at a 2.8% compound annual growth rate (CAGR), from 87.3% to 100%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.